Matinas BioPharma Holdings (MTNB) Shares Outstanding (Weighted Average) (2013 - 2026)

Matinas BioPharma Holdings (MTNB) has 14 years of Shares Outstanding (Weighted Average) data on file, last reported at $6.4 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $6.4 million, up 25.93% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.4 million (up 25.93% YoY), and the FY2025 annual result was $5.5 million, up 12.5% from the prior year.
• Shares Outstanding (Weighted Average) advanced to $6.4 million in Q1 2026 per MTNB's latest filing, from $5.5 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $217.3 million in Q1 2023 and troughed at $4.3 million in Q3 2023.
• A 5-year average of $79.8 million and a median of $5.2 million in 2025 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2024 and 2026: Shares Outstanding (Weighted Average) tumbled 98.0% in 2024, then gained 25.93% in 2026.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $216.8 million in 2022, then plunged by 98.0% to $4.3 million in 2023, then grew by 11.98% to $4.9 million in 2024, then gained by 12.5% to $5.5 million in 2025, then climbed by 17.03% to $6.4 million in 2026.
• Business Quant data shows MTNB's Shares Outstanding (Weighted Average) at $6.4 million in Q1 2026, $5.5 million in Q4 2025, and $5.2 million in Q3 2025.